AU2003294488B2 - Use of HMGB fragments as anti-inflammatory agents - Google Patents

Use of HMGB fragments as anti-inflammatory agents Download PDF

Info

Publication number
AU2003294488B2
AU2003294488B2 AU2003294488A AU2003294488A AU2003294488B2 AU 2003294488 B2 AU2003294488 B2 AU 2003294488B2 AU 2003294488 A AU2003294488 A AU 2003294488A AU 2003294488 A AU2003294488 A AU 2003294488A AU 2003294488 B2 AU2003294488 B2 AU 2003294488B2
Authority
AU
Australia
Prior art keywords
box
hmgb
polypeptide
antibody
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2003294488A
Other languages
English (en)
Other versions
AU2003294488A1 (en
Inventor
Walter Newman
Theresa L. O'keefe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chiesi USA Inc
Original Assignee
Critical Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Critical Therapeutics Inc filed Critical Critical Therapeutics Inc
Publication of AU2003294488A1 publication Critical patent/AU2003294488A1/en
Application granted granted Critical
Publication of AU2003294488B2 publication Critical patent/AU2003294488B2/en
Priority to AU2007205777A priority Critical patent/AU2007205777A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
AU2003294488A 2002-11-20 2003-11-20 Use of HMGB fragments as anti-inflammatory agents Ceased AU2003294488B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2007205777A AU2007205777A1 (en) 2002-11-20 2007-08-13 Use of HMGB fragments as anti-inflammatory agents

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US42784102P 2002-11-20 2002-11-20
US42784602P 2002-11-20 2002-11-20
US60/427,846 2002-11-20
US60/427,841 2002-11-20
PCT/US2003/037507 WO2004046345A2 (en) 2002-11-20 2003-11-20 Use of hmgb fragments as anti-inflammatory agents

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2007205777A Division AU2007205777A1 (en) 2002-11-20 2007-08-13 Use of HMGB fragments as anti-inflammatory agents

Publications (2)

Publication Number Publication Date
AU2003294488A1 AU2003294488A1 (en) 2004-06-15
AU2003294488B2 true AU2003294488B2 (en) 2007-05-24

Family

ID=32329191

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003294488A Ceased AU2003294488B2 (en) 2002-11-20 2003-11-20 Use of HMGB fragments as anti-inflammatory agents

Country Status (6)

Country Link
EP (1) EP1569684A4 (https=)
JP (1) JP2006510619A (https=)
AU (1) AU2003294488B2 (https=)
CA (1) CA2506328A1 (https=)
NZ (1) NZ540067A (https=)
WO (1) WO2004046345A2 (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303321B1 (en) 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
US7304034B2 (en) 2001-05-15 2007-12-04 The Feinstein Institute For Medical Research Use of HMGB fragments as anti-inflammatory agents
US7696169B2 (en) 2003-06-06 2010-04-13 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
WO2005025604A2 (en) * 2003-09-10 2005-03-24 The General Hospital Corporation Use of hmgb and hmgb fragments to decrease specific immune response
CA2882022A1 (en) 2003-09-11 2005-03-24 Walter Newman Monoclonal antibodies against hmgb1
PL1768677T3 (pl) * 2004-07-02 2009-01-30 Creabilis Therapeutics Spa Kwasy nukleinowe do leczenia patologii związanych z HMGB-1
WO2006012373A2 (en) * 2004-07-20 2006-02-02 Critical Therapeutics, Inc. Combination therapies of hmgb and complement inhibitors against inflammation
NZ553809A (en) * 2004-09-03 2010-03-26 Creabilis Therapeutics Spa Use of polypeptides obtained through systematic mutations of single amino acids of human and non-human box-A of HMGB1 to prevent and/or antagonize pathologies induced by HMGB1
US7585504B2 (en) * 2004-10-22 2009-09-08 Medimmune, Llc High affinity antibodies against HMGB1 and methods of use thereof
EP1899376A2 (en) * 2005-06-16 2008-03-19 The Feinstein Institute for Medical Research Antibodies against hmgb1 and fragments thereof
WO2007011606A2 (en) * 2005-07-18 2007-01-25 Critical Therapeutics, Inc. USE OF HMGBl ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY SKIN CONDITIONS
WO2007031100A1 (en) * 2005-09-14 2007-03-22 Ostini, Marco Active immunotherapy of life-threatening systemic inflammation
EP1957534A1 (en) * 2005-11-09 2008-08-20 Pharmexa A/S Therapeutic vaccines targeting hmgb1
AU2007296843C1 (en) 2006-09-15 2012-08-16 Creabilis Therapeutics S.P.A. Polymer conjugates of Box-A of HMGB1 and Box-A variants of HMGB1
PT2066339E (pt) 2006-09-18 2014-10-31 Texas A & M Univ Sys Composições e métodos de potenciar respostas imunes
WO2008099913A1 (ja) 2007-02-15 2008-08-21 Kumamoto University ヒトhmgb-1に特異的に結合する抗体を有効成分として含有する治療剤
ES2654542T3 (es) 2008-04-30 2018-02-14 Genomix Co., Ltd. Procedimiento de recolección de células funcionales in vivo con alta eficiencia
US11191786B2 (en) 2009-10-28 2021-12-07 StemRIM Inc. Agents for promoting tissue regeneration by recruiting bone marrow mesenchymal stem cells and/or pluripotent stem cells into blood
US8956618B2 (en) 2010-01-21 2015-02-17 The Texas A&M University System Vaccine vectors and methods of enhancing immune responses
NZ604412A (en) 2010-06-09 2015-01-30 Univ Arkansas Vaccine and methods to reduce campylobacter infection
EP2703487B1 (en) 2011-04-26 2018-06-27 Genomix Co., Ltd. Peptide for inducing regeneration of tissue and use thereof
AU2013335684B2 (en) 2012-10-25 2017-06-29 Osaka University Novel method for treating cardiac infarction using HMGB1 fragment
DK2913059T3 (en) 2012-10-25 2018-06-25 Genomix Co Ltd Hitherto UNKNOWN PROCEDURE FOR TREATMENT OF SPINE INJURY USING HMGB1 FRAGMENT
US9550825B2 (en) 2013-01-28 2017-01-24 Evec Inc. Humanized anti-HMGB1 antibody or antigen-binding fragment thereof
HUE047484T2 (hu) 2013-02-14 2020-04-28 Univ Arkansas Készítmények és eljárások eimeria elleni immunválasz fokozására vagy eimeria-fertõzés korlátozására
CA2906079C (en) 2013-03-15 2022-08-23 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to enteric pathogens
KR20190015712A (ko) 2016-05-03 2019-02-14 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 면역자극 및 항원 폴리펩티드를 포함하는 효모 백신 벡터, 및 그를 이용하는 방법
US11969459B2 (en) 2017-01-27 2024-04-30 StemRIM Inc. Therapeutic agent for cardiomyopathy, old myocardial infarction and chronic heart failure
AU2018236271B2 (en) 2017-03-15 2023-12-21 Research Institute At Nationwide Children's Hospital Composition and methods for disruption of bacterial biofilms without accompanying inflammation
CA3084013A1 (en) 2017-12-01 2019-06-06 StemRIM Inc. Ectodermal mesenchymal stem cells and method for producing same
WO2019107530A1 (ja) * 2017-12-01 2019-06-06 株式会社ステムリム 炎症性腸疾患の治療薬
WO2019156137A1 (ja) * 2018-02-08 2019-08-15 株式会社ステムリム 乾癬の治療薬
US12304933B2 (en) 2018-10-05 2025-05-20 StemRIM Inc. Disease treatment drug based on mesenchymal-stem-cell mobilization
SG11202103001PA (en) * 2018-10-05 2021-04-29 Res Inst Nationwide Childrens Hospital Hmgb1 protein derivatives for the removal of biofilms cross-reference to related application
CN111743890A (zh) * 2019-03-26 2020-10-09 深圳先进技术研究院 水绫霉素或其衍生物的用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6448223B1 (en) * 1999-02-11 2002-09-10 North Shore - Long Island Jewish Research Institute Antagonists of HMG1 for treating inflammatory conditions

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2296792A1 (en) * 1999-02-26 2000-08-26 Genset S.A. Expressed sequence tags and encoded human proteins

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6448223B1 (en) * 1999-02-11 2002-09-10 North Shore - Long Island Jewish Research Institute Antagonists of HMG1 for treating inflammatory conditions
US6468533B1 (en) * 1999-02-11 2002-10-22 North Shore-Long Island Jewish Research Institute Antagonists of HMG1 for treating inflammatory conditions

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ABRAHAM et al. HMG-1 as a mediator of acute lung inflammation. J. Immunol. 15 September 2000, Vol. 165, No. 6, page 2950-2954. *
ANDERSSON et al. High mobility group 1 protein (HMG-1) stimulates pro-inflammatory cytokine synthesis in human monocytes. J. Exp. Med. 21 August 2000, Vol. 192, No. 4 page 565-570. *
Wang et al. HMG-1 as a late mediator of endotoxin lethality in mice Science 9 July 1999, Vol. 285, No. 5425, page 248-251. *

Also Published As

Publication number Publication date
JP2006510619A (ja) 2006-03-30
NZ540067A (en) 2007-05-31
AU2003294488A1 (en) 2004-06-15
CA2506328A1 (en) 2004-06-03
EP1569684A4 (en) 2006-08-02
WO2004046345A2 (en) 2004-06-03
WO2004046345A3 (en) 2004-12-02
EP1569684A2 (en) 2005-09-07

Similar Documents

Publication Publication Date Title
AU2003294488B2 (en) Use of HMGB fragments as anti-inflammatory agents
US7749959B2 (en) Use of HMGB fragments as anti-inflammatory agents
AU2002309829B2 (en) Use of HMG fragment as anti-inflammatory agents
US20080124320A1 (en) Use of HMGB fragments as anti-inflammatory agents
AU2002309829A1 (en) Use of HMG fragment as anti-inflammatory agents
JP2005512507A6 (ja) 抗炎症剤としてのｈｍｇフラグメントの使用
US20060111287A1 (en) Acetylated protein
EA003675B1 (ru) Белки, связывающие интерлейкин-18, их получение и применение
US20040156851A1 (en) HMGB1 combination therapies
JP2003532370A (ja) 新規なＴｈ２特異的分子およびその使用方法
US5905146A (en) DNA binding protein S1-3
JP2004532042A (ja) Ｂｃｌ−２調節因子（ＢＭＦ）配列及びアポトーシスの調節におけるそれらの使用
AU2007234583B2 (en) Use of HMG fragment as anti-inflammatory agents
AU2007205777A1 (en) Use of HMGB fragments as anti-inflammatory agents
KR20010085816A (ko) 면역 관련 질환 치료용 조성물 및 치료 방법
JP2003000271A (ja) 新規ポリぺプチド、新規ｄｎａ、新規抗体および新規遺伝子改変動物
HK40084870A (en) Biological macromolecular target-specific complement inhibitor, preparation method therefor, and application thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired